IL124417A - מלח מזילתי של -13[(דימתיל אמינו) מתיל] - 10, 11, 14, 15 - טטרה הידרו- 4, 9: 16, 21 - דימתנו - h13, h1 - דיבנזו {e, k} פירולו [h-4, 3] [1, 4, 13] אוקזאדיאזאציקלוהקסאדצין - 1, 3 (h2) - דיון, הכנתו ותכשירי רוקחות לעיכוב פרוטאין קינזה c המכילים אותו - Google Patents

מלח מזילתי של -13[(דימתיל אמינו) מתיל] - 10, 11, 14, 15 - טטרה הידרו- 4, 9: 16, 21 - דימתנו - h13, h1 - דיבנזו {e, k} פירולו [h-4, 3] [1, 4, 13] אוקזאדיאזאציקלוהקסאדצין - 1, 3 (h2) - דיון, הכנתו ותכשירי רוקחות לעיכוב פרוטאין קינזה c המכילים אותו

Info

Publication number
IL124417A
IL124417A IL12441796A IL12441796A IL124417A IL 124417 A IL124417 A IL 124417A IL 12441796 A IL12441796 A IL 12441796A IL 12441796 A IL12441796 A IL 12441796A IL 124417 A IL124417 A IL 124417A
Authority
IL
Israel
Prior art keywords
salt
compound
reaction
water
methyl
Prior art date
Application number
IL12441796A
Other languages
English (en)
Other versions
IL124417A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL124417A0 publication Critical patent/IL124417A0/xx
Publication of IL124417A publication Critical patent/IL124417A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12441796A 1995-11-20 1996-11-18 מלח מזילתי של -13[(דימתיל אמינו) מתיל] - 10, 11, 14, 15 - טטרה הידרו- 4, 9: 16, 21 - דימתנו - h13, h1 - דיבנזו {e, k} פירולו [h-4, 3] [1, 4, 13] אוקזאדיאזאציקלוהקסאדצין - 1, 3 (h2) - דיון, הכנתו ותכשירי רוקחות לעיכוב פרוטאין קינזה c המכילים אותו IL124417A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US697095P 1995-11-20 1995-11-20
PCT/US1996/018512 WO1997018809A1 (en) 1995-11-20 1996-11-18 Protein kinase c inhibitor

Publications (2)

Publication Number Publication Date
IL124417A0 IL124417A0 (en) 1998-12-06
IL124417A true IL124417A (he) 2002-11-10

Family

ID=21723527

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12441796A IL124417A (he) 1995-11-20 1996-11-18 מלח מזילתי של -13[(דימתיל אמינו) מתיל] - 10, 11, 14, 15 - טטרה הידרו- 4, 9: 16, 21 - דימתנו - h13, h1 - דיבנזו {e, k} פירולו [h-4, 3] [1, 4, 13] אוקזאדיאזאציקלוהקסאדצין - 1, 3 (h2) - דיון, הכנתו ותכשירי רוקחות לעיכוב פרוטאין קינזה c המכילים אותו

Country Status (34)

Country Link
US (3) US5710145A (he)
EP (1) EP0776895B1 (he)
JP (1) JP3348859B2 (he)
KR (1) KR100304210B1 (he)
CN (1) CN1093759C (he)
AR (2) AR004336A1 (he)
AT (1) ATE172199T1 (he)
AU (1) AU711125B2 (he)
BR (1) BR9611724A (he)
CA (1) CA2237221C (he)
CO (1) CO4750823A1 (he)
CY (1) CY2103B1 (he)
CZ (1) CZ297524B6 (he)
DE (1) DE69600784T2 (he)
DK (1) DK0776895T3 (he)
EA (1) EA000967B1 (he)
EG (1) EG23871A (he)
ES (1) ES2122764T3 (he)
HU (1) HU226821B1 (he)
IL (1) IL124417A (he)
MX (1) MX9803792A (he)
MY (1) MY118068A (he)
NO (1) NO310196B1 (he)
NZ (1) NZ323571A (he)
PE (1) PE22798A1 (he)
PL (1) PL184715B1 (he)
RO (1) RO120074B1 (he)
SI (1) SI0776895T1 (he)
TR (1) TR199800759T2 (he)
TW (1) TW403754B (he)
UA (1) UA61897C2 (he)
WO (1) WO1997018809A1 (he)
YU (1) YU49315B (he)
ZA (1) ZA969646B (he)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
JP3646651B2 (ja) * 1998-01-30 2005-05-11 ダイソー株式会社 ブタントリオール誘導体の製造法
US6225301B1 (en) 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6291446B1 (en) * 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
EP1070068B2 (en) * 1998-03-13 2007-01-17 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
AU7025201A (en) * 2000-07-03 2002-01-14 Gala Design Inc Expression vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US6300106B1 (en) * 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
JP2005531544A (ja) * 2002-05-06 2005-10-20 ワシントン・ユニバーシティ Ｅｇｆｒ経路の抑制による緑内障およびｎｏｓ−２発現により媒介される他の状態の治療方法
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) * 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
DE602004025569D1 (de) 2003-06-18 2010-04-01 Tranzyme Pharma Inc Makrozyklische motilin rezeptorantagonisten
US20050152942A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
JP2007529434A (ja) * 2004-03-17 2007-10-25 ラース マイケル ラーセン， 視覚サイクルの阻害による網膜症の予防
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
WO2006068988A1 (en) * 2004-12-20 2006-06-29 Eli Lilly And Company Combination therapy for vascular complications associated with hyperglycemia
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
WO2008027619A2 (en) 2006-09-01 2008-03-06 Intermec Ip Corp. Rfid tag system with block coding, such as space-time block coding
PE20091522A1 (es) * 2007-12-21 2009-10-29 Novartis Ag Composicion farmaceutica solida que contiene 3-(1.h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-quinazolin-4-il]-pirrol-2,5-diona
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
EP2552428A1 (en) 2010-03-30 2013-02-06 Novartis AG Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
PL2925366T3 (pl) 2012-11-29 2018-08-31 Novartis Ag Kombinacje farmaceutyczne
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US20180185259A1 (en) 2016-12-19 2018-07-05 Chromaderm, Inc. Methods of treating hyperpigmentation disorders
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
US11590131B2 (en) 2017-07-28 2023-02-28 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
KR20230005944A (ko) 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
PL182124B1 (pl) * 1993-12-07 2001-11-30 Lilly Co Eli Nowe zwiazki oraz srodek farmaceutyczny przeznaczony do leczenia powiklan cukrzycowych lub do leczenia nowotworów PL PL PL PL PL PL PL PL
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
ES2122764T3 (es) 1998-12-16
JP3348859B2 (ja) 2002-11-20
US6015807A (en) 2000-01-18
AR004336A1 (es) 1998-11-04
HU226821B1 (en) 2009-11-30
NZ323571A (en) 1998-12-23
NO982182L (no) 1998-05-13
TW403754B (en) 2000-09-01
EG23871A (en) 2007-11-27
US6117861A (en) 2000-09-12
DE69600784T2 (de) 1999-04-08
NO310196B1 (no) 2001-06-05
AR004717A1 (es) 1999-03-10
AU711125B2 (en) 1999-10-07
WO1997018809A1 (en) 1997-05-29
EA000967B1 (ru) 2000-08-28
AU1054897A (en) 1997-06-11
MY118068A (en) 2004-08-30
CZ297524B6 (cs) 2007-01-03
IL124417A0 (en) 1998-12-06
YU60996A (sh) 1999-03-04
BR9611724A (pt) 1999-06-01
EA199800374A1 (ru) 1998-10-29
DK0776895T3 (da) 1999-06-23
SI0776895T1 (en) 1999-04-30
PL184715B1 (pl) 2002-12-31
KR100304210B1 (ko) 2001-11-05
TR199800759T2 (xx) 2001-01-22
EP0776895B1 (en) 1998-10-14
KR19990067596A (ko) 1999-08-25
ZA969646B (en) 1998-05-18
PE22798A1 (es) 1998-05-11
CO4750823A1 (es) 1999-03-31
NO982182D0 (no) 1998-05-13
HUP9903377A3 (en) 2000-04-28
CN1093759C (zh) 2002-11-06
UA61897C2 (en) 2003-12-15
MX9803792A (es) 1998-09-30
CA2237221C (en) 2003-03-25
JPH11500149A (ja) 1999-01-06
HUP9903377A2 (hu) 2000-02-28
CN1202825A (zh) 1998-12-23
YU49315B (sh) 2005-06-10
CA2237221A1 (en) 1997-05-29
RO120074B1 (ro) 2005-08-30
ATE172199T1 (de) 1998-10-15
PL326754A1 (en) 1998-10-26
CY2103B1 (en) 2002-04-05
DE69600784D1 (de) 1998-11-19
US5710145A (en) 1998-01-20
EP0776895A1 (en) 1997-06-04
CZ150298A3 (cs) 1998-12-16

Similar Documents

Publication Publication Date Title
US6117861A (en) Protein kinase C inhibitor
TWI299731B (en) Selected fused pyrrolocarbazoles
RU2089550C1 (ru) Производное 1,4-бензотиазепина
PL166209B1 (pl) Sposób wytwarzania nowych pochodnych benzimidazolu PL
BR112021001309A2 (pt) método para a preparação da 2-[(3r)-3-metilmorfolin-4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina
JP2008138006A (ja) Ｎ，ｎ’−架橋ビスインドリルマレイミドの製造における新規中間体およびその用途
JPH0249788A (ja) ピラノベンゾオキサジアゾール誘導体
JP2024506387A (ja) 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤
CA2896209A1 (fr) 3,5-diaryl-azaindoles comme inhibiteurs de la proteine dyrk1a pour le traitement des deficiences cognitives liees au syndrome de down et a la maladie d'alzheimer
US5721272A (en) Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
RU2128043C1 (ru) Лекарственные средства для сердечной недостаточности
RU2051916C1 (ru) Оптически активные производные индолбензохинолина или их фармацевтически приемлемые соли

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees